Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an
individual's life and on society. Thus, developing more effective therapeutic interventions is …

Abstract N-methyl-d-aspartate (NMDA) receptor (NMDAR) hypofunction plays a key role in
pathophysiology of schizophrenia. Since NMDAR hypofunction has also been reported in …

The NMDA-R hypofunction model of schizophrenia started with the clinical observation of
the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or …

Schizophrenia is a severe mental illness that affects almost 1% of the population worldwide.
Even though the etiology of schizophrenia is uncertain, it is believed to be a …

N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP),
dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia …

Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …

Recent theoretical accounts have proposed excitation and inhibition (E/I) imbalance as a
possible mechanistic, network-level hypothesis underlying neural and behavioral …

Acute administration of (R, S)-ketamine (ketamine) produces rapid antidepressant effects
that in some patients can be sustained for several days to more than a week. Ketamine …

Brain function relies on the ability of neural networks to maintain stable levels of activity,
while experiences sculpt them. In the neocortex, the balance between activity and stability …